Detalhe da pesquisa
1.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med
; 372(4): 311-9, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482239
2.
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Cancer
; 123(19): 3807-3815, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28608950
3.
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.
J Pathol
; 235(3): 478-89, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25348195
4.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med
; 366(26): 2455-65, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658128
5.
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Cancer Immun
; 13: 5, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23390376
6.
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
J Transl Med
; 11: 89, 2013 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23557194
7.
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.
Prostate
; 72(5): 514-22, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21761425
8.
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
J Immunol
; 182(11): 6659-69, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19454660
9.
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.
J Immunol
; 182(8): 4675-85, 2009 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19342643
10.
Tc17 CD8 T cells: functional plasticity and subset diversity.
J Immunol
; 183(11): 7161-8, 2009 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19917680
11.
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
J Clin Invest
; 117(11): 3383-92, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17932562
12.
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
JAMA Oncol
; 5(10): 1411-1420, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31343665
13.
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
Prostate
; 68(12): 1319-29, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18561247
14.
Current immunotherapeutic strategies in prostate cancer.
Surg Oncol Clin N Am
; 16(4): 861-71, x, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18022549
15.
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models.
Oncoimmunology
; 7(1): e1377873, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296539
16.
A unique mucin immunoenhancing peptide with antitumor properties.
Cancer Res
; 64(21): 8077-84, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15520219
17.
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
J Clin Oncol
; 34(23): 2698-704, 2016 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27269947
18.
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.
Int J Radiat Oncol Biol Phys
; 87(4): 769-76, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24064321
19.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Cancer Res
; 72(4): 917-27, 2012 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22186141
20.
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.
Mol Immunol
; 47(7-8): 1595-600, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20226531